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Abstract
Background: The nutrigenomics, overweight/obesity and weight management trial (NOW Trial) is a pragmatic
randomized controlled trial of community-dwelling adults recruited from the Group Lifestyle Balance™ (GLB™)
Program. The GLB™ Program (formerly referred to as the Diabetes Prevention Program) is an evidence-based,
intensive weight management program, which was offered to overweight/obese patients (BMI ≥ 25.0 kg/m2) in a
rural Ontario community.
Methods: Patients enrolled in the GLB™ Program were invited to participate in this study. GLB™ groups were
randomized 1:1 to receive either the standard GLB™ program + population-based lifestyle advice for weight
management, or a modified GLB™ program + personalized, genetic-based lifestyle advice for weight management.
The purpose of this study is to determine if the provision of genetic-based lifestyle guidelines is superior to the
provision of population-based guidelines in a pragmatic clinical setting to promote changes in: body composition,
weight, body mass index, dietary and physical activity habits, as well as attitudes, subjective norms, and behavioural
control. The 12-month intervention protocol consists of 23 group-based sessions and 4 one-on-one sessions. Data
collection time points include baseline in addition to 3, 6, and 12-month follow up. The comprehensive study
design is described in the present manuscript, using both the extended CONSORT checklist for reporting pragmatic
trials and the SPIRIT checklist as guidance during manuscript development.
Discussion: Overall, this study seeks to pragmatically determine if the provision of DNA-based lifestyle advice leads
to improved health and lifestyle outcomes compared to the provision of standard, population-based lifestyle advice.
The results of this trial can be used to inform clinical and community nutrition practice guidelines.
Trial registration: This study was registered with clinicaltrials.gov: NCT03015012 on January 9, 2017.
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Background
Lifestyle modification of nutrition and physical activity
are often recommended to help manage overweight and
obesity [1]. Despite increased knowledge of beneficial
lifestyle strategies for weight management, rates of over-
weight and obesity continue to climb among adults in
Canada and the United States [2, 3]. The Group Lifestyle
Balance™ (GLB™) program is one of the most successful
lifestyle-based weight management programs and is cur-
rently offered in over 80 primary care settings in the
United States and is now becoming increasingly preva-
lent in Canada [4]. The GLB™ program was originally
intended only for individuals with prediabetes and was
formerly referred to as The Diabetes Prevention Pro-
gram (DPP). In patients with prediabetes, the DPP life-
style intervention reduced the risk of progressing to type
2 diabetes by 58%, while the biguanide antihyperglyce-
mic agent, Metformin, reduced the risk of type 2 dia-
betes by 31% when compared to a placebo pill [5]. Given
the documented success of the DPP, the Ontario Minis-
try of Health and Long-Term Care encouraged program
expansion through broader eligibility criteria [6], and as
such some clinics are now offering this program for gen-
eral weight management (regardless of receiving a predi-
abetes diagnosis), since overweight and obesity are
considered risk factors for the development of type 2
diabetes [7].
Although the GLB™ program has proven to be success-
ful [5, 8, 9], a “one-size fits all” approach to weight man-
agement has been critiqued by experts, who argue that
this generalized approach yields minimal weight loss
outcomes that do not satisfy the wants and needs of cli-
nicians, researchers and patients alike [10]. Genetic test-
ing is an innovative tool, which has the potential to
facilitate positive lifestyle changes and enhance patient
outcomes, though this has been widely debated in the
literature in recent years [11–14]. A systematic review
found that actionable lifestyle recommendations (e.g.,
“reduce your consumption of sodium”) facilitated behav-
iour change greater than the provision of simple
genetic-based disease-risk estimates, and that nutrition
was the most promising lifestyle habit that could be mo-
tivated by lifestyle genomics testing [11].
A few studies have assessed change in weight from the
provision of genetic-based information compared to a
standard intervention [15–17]. Two studies reported
that genetic testing was superior to a standard interven-
tion for changes in weight or BMI [15, 17], and one
study showed that adherence to a genetic-based diet was
correlated with greater weight loss, whereas adherence
to a standard diet was not [16].
There have been considerable scientific advancements
in knowledge pertaining to nutrition and physical activ-
ity recommendations, which can be personalized based
on an individual’s genetic variation. Nutrigenomics is a
science that explores the interaction between nutrition,
genetics, and health outcomes [18]. The science explor-
ing how nutrition and physical activity, alongside other
lifestyle components, can impact health outcomes can
be referred to as lifestyle genomics [11]. Single nucleotide
polymorphisms (SNPs) located within the genes FTO,
MC4R, TCF7L2, UCP1, APOA2, and PPARg2 can im-
pact physical activity and dietary approaches to weight
management and/or nutritional habits [19–27]. Further-
more, SNPs located within the genes ACTN3,
NFIA-AS2, ADRB3, NRF2 and GSTP1 have been shown
to impact genetic predisposition to excel in either endur-
ance or strength-based activities [28–32]. These genetic
variants were used in the genetic test provided in the
present study as they are currently offered through com-
mercial genetic testing [33], thus optimizing the prag-
matic nature of this trial.
While genetics certainly plays a role in obesity, there
are multiple factors contributing to the current obesity
epidemic, including diminished energy expenditure, in-
creased energy intake, rising food costs, the built envir-
onment, socioeconomic status, and other social
determinants of health [34–39]. Several of these factors
can be modified such as energy intake and energy
expenditure.
The Theory of Planned Behaviour (TPB) posits that at-
titudes towards a behaviour, subjective norms, perceived
behavioural control and actual behavioural control can
be used to predict intentions and behaviours [40]. Al-
though the TPB is one of the most widely-accepted be-
haviour change theories, it has yet to be incorporated
into genetic testing behaviour change research [11, 41]
despite a recent call to incorporate this theory into per-
sonalized healthcare behaviour change research [41]. By
considering this theory, we can account for many con-
tributors impacting behaviour change and therefore ac-
count for several confounding factors, which could
influence study results. The present randomized con-
trolled trial is the first study to intentionally incorporate
the TPB into genetic testing behaviour change research.
The proposed extended CONSORT checklist for
reporting pragmatic trials [42] was used to guide the de-
velopment of the current manuscript. The complete
checklist can be reviewed in Additional file 1, with items
1 through 16 being relevant for purposes of this paper.
Methods/design
Objectives
The primary objective of this study is to determine if
the provision of genetic-based lifestyle advice reduces
body fat percentage to a greater extent than the
provision of population-based lifestyle advice. Second-
ary objectives include determining whether the
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provision of genetic-based lifestyle advice (a) helps to
motivate healthful changes to dietary intake and phys-
ical activity, (b) leads to greater improvements in an-
thropometric measures such as weight, BMI, lean
mass, fat mass (kg), and water weight, and (c) influ-
ences attitudes, subjective norms, behavioural control,
and intention to make lifestyle changes. The tertiary
objective is to determine if there is a nutrigenomics
interaction between ACE rs4343 genetic variation, so-
dium and water intake, and water weight.
Hypotheses
Compared to the provision of population-based life-
style advice, providing DNA-based lifestyle advice will
lead to significantly greater improvements in: body fat
percentage, attitudes and intentions towards behaviour
change, the adoption of healthier dietary and physical
activity habits, as well as improved weight, and BMI.
Furthermore, we hypothesize that ACE rs4343 genetic
variation will lead to increased water weight when so-
dium intake is high.
Material and methods
The flow of the study protocol for this parallel group,
superiority randomized controlled trial is outlined in
Figs. 1, 2 and 3. Further details are provided below.
Sample size calculation
Seventy-four participants (n = 37 per group) are needed
in this study to detect a clinically meaningful difference
of 4% in body fat percentage, assuming 80% power, an
alpha of 5%, and a standard deviation of 6.1% [43]. We
aimed to recruit 88 participants (n = 44 per group) to ac-
count for the potential dropout rate of 20%. While min-
imal research exists outlining a clinically meaningful
change in body fat percentage, a 5% change in weight
(which would come from fat mass, water weight and/or
muscle mass) is often reported to be clinically meaning-
ful [44]. Furthermore, clinical experience from the regis-
tered dietitians involved in this study helped to
determine the clinically meaningful 4% difference men-
tioned above. This difference has also been supported in
published reference standards of body fat percentage in
Caucasian adults which indicate that a 4% change in
body fat percentage is associated with a 1 – 2 decile
change on the reference standards charts [45].
Cohort randomization
A cohort randomization model was used rather than
subject randomization to allow all participants in a given
GLB™ group to obtain the same intervention. At the
time of randomization, 12 cohorts (GLB™ groups) were
randomized 1:1 to either the personalized lifestyle inter-
vention (PLI) based on genetics, or the standard lifestyle
Fig. 1 Flow of Study Protocol
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intervention (SLI) based on population-based guidelines.
It was anticipated that 12 groups of approximately 7 par-
ticipants each would be needed to obtain the desired
sample size of 88 participants. Prior to obtaining in-
formed consent from participants, randomly permuted
blocks were generated using the original generator on an
internet-based randomization program [46]. Since par-
ticipant recruitment was quicker than anticipated and
there was an even 1:1 split of a PLI and a SLI group in
the last two randomized groups, only 10 of the random-
ized groups (5 PLI groups, 5 SLI groups) were used,
resulting in a total of N = 140 participants in the study
(mean number of study participants per group ± SD =
14.0 ± 4.1).
Recruitment
Participants were recruited from the GLB™ program at
the East Elgin Family Health Team (EEFHT). There were
two primary methods of recruitment into this program:
[1] adults from Elgin and Middlesex Counties in On-
tario, Canada were referred to the GLB™ program by
healthcare professionals in the area such as registered di-
etitians (RDs), physicians, nurses, nurse practitioners,
and physical therapists; and [2] adults joined the pro-
gram through word-of-mouth referrals from members of
the community. Participants expressing interest in
joining the GLB™ program were invited to the EEFHT
for an in-person meeting to learn about the NOW Trial,
and to provide written, informed consent if they decided
to take part in the study. Therefore, participants are
highly reflective of typical patients in the GLB™ program.
Recruitment occurred from April 2017 until September
2018. This study is registered with clinicaltrials.gov
(NCT03015012) and was approved by the Western
University Research Ethics Board (108511).
Participants: Screening & Informed Consent
Screening and informed consent were completed in per-
son at the EEFHT during the in-person meeting. Inclu-
sion criteria were as follows: BMI ≥ 25.0 kg/m2, ≥18 years
of age, English-speaking, willing to undergo genetic test-
ing, having access to a computer with internet at least
one day per week, and not seeing another healthcare
provider for weight loss advice outside of the study.
Pregnancy and lactation were considered exclusion
criteria.
Run-in
Upon obtaining written, informed consent, participants
were scheduled for in-person baseline data collection,
within approximately 14 days (mean ± SD = 9.3 ± 5.7)
Fig. 2 CONSORT 2010 Flow Diagram (Clinical Trial Registration Number: NCT03015012)
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Fig. 3 SPIRIT Flow Diagram of The NOW Trial Study Protocol at the EEFHT. SE: study entry; Mo: month
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prior to the intervention start date. Participants were
not given any lifestyle advice during the run-in period.
Baseline data collection
All data are entered into the database using unique
study codes for each participant and is securely stored in
a locked cabinet, in a locked office. Baseline data con-
sisted of a combination of in-person, online, and tele-
phone data collection methods.
Trained research assistants collected 3-day food re-
cords over the phone using the validated multiple-pass
method [47]. To reduce participant burden, each partici-
pant chose to have either 3 separate phone calls (one for
each day of intake), or 1 phone call (for all three days of
intake). One weekend day and two weekdays were col-
lected. In rare cases where research assistants were un-
able to reach participants over the phone, the food
records were collected in-person at the EEFHT. The
food records were then analyzed using the Canadian Nu-
trient File within the nutritional analysis software pro-
gram ESHA Food Processor (version 11.1).
Participants also completed a self-administered
past-month, semi-quantitative, online food frequency
questionnaire, the Canadian Diet History Questionnaire
II (CDHQII). This questionnaire is a modified version of
the United States Diet History Questionnaire adapted for
Canadian data [48]. Most participants completed this
questionnaire away from the EEFHT, but in cases where
participants did not have internet access at home (n = 3),
the CDHQII was self-administered at the EEFHT.
In-person baseline data collection included: measured
height and weight (used to calculate BMI), a BIA assess-
ment to obtain body composition data (using the Body
Stat 1500MDD), a past-week physical activity recall
(used to calculate metabolic equivalents), a baseline
demographic questionnaire, a list of medications, and a
TPB questionnaire. To optimize reliability, weight and
height measurements were taken on the same Health O
Meter Professional weigh scale and stadiometer, and
body composition was assessed using the same BIA ma-
chine. The TPB questionnaire was developed based on
Ajzen’s Guide to Constructing a TPB Questionnaire [49].
The results for weight, body fat percentage, body fat
(kg), lean weight, and water weight from the BIA were
communicated to participants during their in-person
baseline data collection visit.
To assess possible short-term changes in compo-
nents of the TPB (e.g. attitudes towards nutrition,
physical activity, genetic testing, etc.), the TPB ques-
tionnaire was administered twice during the baseline
assessment period: once during the one-on-one,
in-person meeting (pre-intervention), and once imme-
diately after the first group-based intervention session
was delivered (post-intervention).
Blinding and allocation concealment
During informed consent meetings, baseline data collec-
tion and the run-in period, participants were blinded to
their group assignment. However, participants were not
blinded to their group assignment during the adminis-
tration of the second baseline TPB survey (completed
immediately after the first group session in order to as-
sess possible changes short-term in key components of
the TPB upon receiving either population-based advice
or genetic-based advice). Research assistants collecting
and analyzing food intake data were also blinded to the
study group of the participants and the statistician will
be blinded to the group assignments. Since our out-
comes included changes in attitudes related to genetic
testing for personalized lifestyle advice, as well as change
in nutrition and physical activity habits, it was inappro-
priate to blind the participants throughout the entire
duration of the study. Therefore, participants were in-
formed of their group assignment during the first group
intervention meeting, as further outlined in section 4.9,
below. One author generated the allocation sequence,
enrolled participants, facilitated group and one-on-one
interventions, collected data, entered data into the data-
base and scheduled participants, and therefore could not
be blinded. Allocation was concealed for the other five
co-authors.
Staggered cohorts
Staggered cohorts have been used to reduce the impact
of confounding by indication and have previously been
successful in studies comparing active and passive treat-
ment groups [50]. In the present study, staggered co-
horts were pre-planned in order to maximize study
efficiency and effectiveness. Seasonality and timing of
groups were considered in the planning phase to ensure
that there was a similar amount of SLI groups and PLI
groups offered during the day and evening. Three SLI
groups were offered during the day, and 2 SLI groups
were offered in the evenings. Likewise, 3 PLI groups
were offered during the day, and 2 PLI groups were of-
fered in the evenings. 1 SLI group began in the spring, 2
in the summer, and 2 in the fall. Similarly, 1 PLI group
began in the spring, 2 in the summer, 1 in the fall, and 1
in the winter.
Interventions
Given its previously documented success [5, 8, 9], the
GLB™ program was chosen as the gold standard com-
parator for this RCT. Furthermore, given that this study
is taking place within routine community/clinical prac-
tice, it is highly pragmatic with a mean overall PRECIS-2
score of 4.4 (Table 1) [51].
Participants joined the GLB™ group session that best
suited their availability, and were blinded to the group
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intervention assignment at this time. As previously de-
tailed, groups were pre-randomized 1:1 to receive either
the standard 12-month GLB™ Program curriculum + a
summary report of population-based lifestyle recom-
mendations (SLI/Control Group), or a modified
12-month GLB™ Program + a summary report of
DNA-based lifestyle recommendations (PLI Group). All
participants underwent a group-based weight manage-
ment program in addition to four one-on-one sessions
(one baseline and three follow-up) with a RD. Group
sizes ranged from 7 to 20 participants per group at base-
line, with a mean group size of 14 participants. At the
three follow-up one-on-one sessions, the RD reviewed
the information provided in the summary report (popu-
lation-based recommendations for the SLI group and
DNA-based recommendations for the PLI group; refer
to Additional files 2 and 3, respectively, for sample re-
ports). One-on-one sessions lasted approximately 30
min. The same RD who completed the one-on-one ses-
sions was also the lead trained lifestyle coach for the
GLB™ Program group sessions. This allowed for
optimization of intervention reliability in all group and
one-on-one sessions. These sessions were highly stan-
dardized as outlined in Additional file 4. No additional
healthcare professionals above and beyond standard
practice were hired to run the intervention at the
EEFHT. Interventions took place between May 2017 and
September 2019.
SLI group meetings (control group) The standard
GLB™ Program curriculum involves group-based educa-
tion on a sustainable healthy lifestyle and a
moderately-low-fat, calorie-controlled nutrition plan as
further detailed elsewhere [52]. Standard GLB™ group
sessions were 1 h long. The EEFHT expanded the eligi-
bility criteria for this program and offered it to adults
with a BMI ≥25 kg/m2. In addition to the standard GLB™
Program, participants were provided with an extra 1.5 h
group session (the first session), where they were given
an overview of population-based information and rec-
ommendations for calories, protein, total fat, saturated
fat, total unsaturated fat, monounsaturated fat, polyun-
saturated fat, meal/snack timing, and physical activity.
This information is further detailed in Additional file 2.
Upon completion of the 12-month study, participants in
the SLI group were given the results of their lifestyle
genomics test if they were interested in receiving it.
PLI group meetings (intervention group) The modi-
fied GLB™ Program curriculum is outlined in Additional
file 4. The modifications allowed participants in this
group to follow their DNA-based recommendations, ra-
ther than the standard population-based guidelines. For
example, if an individual possessed a genetic variant in
the FTO gene whereby a moderately high protein diet
can enhance weight loss [21], they were given a target
for protein, and were taught how to count daily grams
of protein (in addition to calories). In comparison, for
the standard GLB™ program, every participant was pro-
vided with a target for total fat intake and were taught
how to count daily fat grams (in addition to calories).
Modified GLB™ group sessions were 1 h long. In addition
to the modified GLB™ Program, participants were pro-
vided with an extra 1.5 h group session (the first ses-
sion), where they were given an overview of personalized
DNA-based information and recommendations for calo-
ries, protein, total fat, saturated fat, total unsaturated fat,
monounsaturated fat, polyunsaturated fat, meal/snack
Table 1 PRECIS-2 Scoring Tool [51]
PRECIS-2 Domain Score [Likert scale 1 (very explanatory)
- 5 (very pragmatic)]
1. Eligibility: To what extent are the participants in the trial similar to those who would receive this
intervention if it was part of usual care?
5
2. Recruitment: How much extra effort is made to recruit participants over and above what would be used in
the usual care setting to engage with patients?
5
3. Setting: How different are the settings of the trial from the usual setting? 5
4. Organization: How different are the resources, provider expertise, and the organization of care delivery in
the intervention arm of the trial from those available in usual care?
4
5. Flexibility (delivery): How different is the flexibility in how the intervention is delivered and the flexibility
anticipated in usual care?
4
6. Flexibility (adherence): How different is the flexibility in how participants are monitored and encouraged to
adhere to the intervention from the flexibility anticipated in usual care?
4
7. Follow-up: How different is the intensity of measurement and follow-up of participants in the trial from the
typical follow-up in usual care?
3
8. Primary outcome: To what extent is the trial’s primary outcome directly relevant to participants? 5
9. Primary analysis: To what extent are all data included in the analysis of the primary outcome? TBD
Mean score: 4.4
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timing, and physical activity. This information is further
detailed in Additional file 3. It should be noted that the
genetic intervention is rated to be high-quality based on
a recently developed genetic intervention quality assess-
ment tool [11]. The quality assessment is outlined in
Additional file 5.
Follow-up data collection
Similar to baseline data collection, follow-up data collec-
tion involved a combination of in-person, online and
telephone data collection methods. All participants were
invited to complete follow-up data collection, regardless
of their compliance to their intervention’s lifestyle rec-
ommendation. Complete follow-up data included: BMI,
3-day food records, the CDHQII past-month online food
frequency questionnaire, BIA, a past-week physical activ-
ity recall, a follow-up demographic survey and medica-
tion list, and a TPB questionnaire. Further details of
these measures are indicated above in section 4.6. The
TPB questionnaire was administered once at each
follow-up time point during the one-on-one in-person
sessions. In addition, at the 12-month follow-up, partici-
pants were asked one open-ended question: How has
your life changed since you started participating in this
program/study (if at all)? Follow-up data collection com-
menced in August 2017 and is ongoing until September
2019.
Statistical analysis plan
We plan to use SPSS Version 23.0 to conduct all statis-
tical analyses, and the data will be analyzed on an
intention-to-treat basis. Generalized linear mixed-effects
models will be used to test between group differences
from baseline to each follow-up period for each outcome
indicator. If significant mean differences are detected, a
Tukey’s post hoc test will be used to compare differences
by group. General linear regression models will be used
to assess interactions between a given genotype of inter-
est and dietary component of interest on BMI and body
composition. General linear regression models will fur-
ther be used to assess interactions between TPB compo-
nents, study group, and anthropometric measures of
weight and body composition. No interim analyses will
be completed.
Outcomes
The primary outcome in this study is change in percent
body fat. Secondary outcome measures include changes
in: dietary intake (calories, fat, protein, carbohydrates,
unsaturated fat including mono- and poly-unsaturated
fat, saturated fat, and sodium), physical activity, atti-
tudes, subjective norms, behavioural control, intention
to make lifestyle changes, weight and BMI.
Dissemination
We plan to disseminate the findings from this trial
through: a community presentation to the participants
involved in the study, presentations at relevant confer-
ences for researchers and healthcare professionals, as
well as in peer-reviewed publications.
Discussion
The overarching aim of this study is to determine if pa-
tients have improved health and lifestyle outcomes with
the provision of DNA-based lifestyle information and rec-
ommendations, compared to the provision of standard,
population-based lifestyle advice. Furthermore, it aims to
test the aforementioned hypotheses, based on lifestyle
genomics weight management advice available to con-
sumers globally through commercial genetic testing. This
highlights the pragmatic nature of this trial, and optimizes
the potential for knowledge translation on a global-scale.
The NOW Trial protocol differs from previous re-
search in that it was designed pragmatically, using a
knowledge translation approach. Furthermore, the
NOW Trial aims to compare a DNA-based lifestyle
change program to the gold standard, population-based
lifestyle change program (the GLB™ Program), while
considering and accounting for major confounding fac-
tors of behaviour change. It is also the first lifestyle gen-
omics weight management and behaviour change study
to incorporate the TPB into the study design; this may
help target a sub-set of the population that may benefit
most from genetic testing for weight management. This
trial is also unique because the genetic information was
presented to participants in a group setting, thus dem-
onstrating the feasibility of this more efficient approach
to the delivery of genetic information.
Pragmatic clinical trials are distinguished by their
focus on informing clinical practice rather than confirm-
ing a physiological or clinical hypothesis. Notably, prag-
matic trials help to inform real-world research questions
that are applicable to broad patient groups [53]. Given
the novel and pragmatic nature of the study, the NOW
Trial provides several original contributions to the litera-
ture. Overall, the NOW Trial will provide important, in-
novative health knowledge relevant to researchers,
academia, consumers, the genetic testing industry, clini-
cians and public health authorities.
Additional Files
Additional file 1: Proposed Extended CONSORT Checklist of Items for
Reporting Pragmatic Trials [42]. Checklist of items to include in a
pragmatic RCT (DOCX 18 kb)
Additional file 2: Sample Report for Standard Lifestyle Intervention
(Control Group). Sample population-based lifestyle recommendations and
information provided to the control group (DOCX 13 kb)
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Additional file 3: Sample Report for Personalized Lifestyle Intervention.
Sample genetic-based lifestyle recommendations and information pro-
vided to the lifestyle genomics intervention group (DOCX 14 kb)
Additional file 4: GLB™ Program [52]/NOW Trial Curriculum and
Modifications for Genetic Testing Intervention Groups. Legend for
Additional file 4. 1. The physical activity goal and references to fat grams
were verbally modified in the “To Do” lists at the end of sessions.
Participants were reminded about how response to different diets and
physical activity for weight loss differ from person to person. Based on
their personalized genetic report, participants were advised and taught
how to reach their personal nutrition and physical activity goals. This
modification occurred throughout the GLB™ Program’s “To Do” lists and
is not included in Additional file 4. 2. The GLB™ Curriculum begins in
class 2. Class 1 allows for an overview of nutrition and physical activity
guidelines either based on [1] the Acceptable Macronutrient Distribution
Ranges and population-based health information and recommendations
or [2] genetic-based information and recommendations. Refer to Add-
itional files 2 and 3 for sample reports provided in class 1. 3. Participants
were informed about how the program is typically used for individuals
with pre-diabetes, since our population consisted of overweight/obese
adults who may or may not have pre-diabetes or type 2 diabetes.
(DOCX 19 kb)
Additional file 5: Quality Assessment Tool for Genetic Interventions [11].
Legend for Additional file 5. *CD, cannot determine; NR, not reported;
NA, not applicable (DOCX 13 kb)
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